Statistical Analysis.—This study was designed to
assess the efficacy and safety of a combined pharmaceutical
modality including SPr in patients commonly
affected by moderate to severe migraine attacks. The
primary efficacy end point was the proportion of
patients experiencing headache-free response 2 hours
after dosing.